SI-BONE, Inc. (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 3,309 Shares

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 3,309 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $12.92, for a total transaction of $42,752.28. Following the transaction, the insider now directly owns 243,629 shares in the company, valued at approximately $3,147,686.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

SI-BONE Price Performance

Shares of NASDAQ:SIBN traded down $0.05 during trading hours on Friday, hitting $12.99. 192,854 shares of the company’s stock traded hands, compared to its average volume of 404,186. SI-BONE, Inc. has a 52 week low of $11.76 and a 52 week high of $27.86. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.75 and a current ratio of 9.76. The company’s fifty day simple moving average is $13.69 and its two-hundred day simple moving average is $16.75. The company has a market cap of $535.25 million, a price-to-earnings ratio of -11.84 and a beta of 1.20.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. The company had revenue of $37.87 million during the quarter, compared to analyst estimates of $36.45 million. As a group, equities analysts anticipate that SI-BONE, Inc. will post -0.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $27.00 target price on shares of SI-BONE in a research note on Tuesday, May 7th. Morgan Stanley lowered their target price on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 7th. Piper Sandler assumed coverage on shares of SI-BONE in a research note on Thursday, March 28th. They set an “overweight” rating and a $25.00 target price on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of SI-BONE in a research note on Tuesday, May 7th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $26.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Brown Advisory Inc. boosted its holdings in shares of SI-BONE by 5.4% in the fourth quarter. Brown Advisory Inc. now owns 4,207,703 shares of the company’s stock worth $88,320,000 after buying an additional 214,089 shares during the period. First Light Asset Management LLC lifted its position in shares of SI-BONE by 0.9% in the fourth quarter. First Light Asset Management LLC now owns 2,547,392 shares of the company’s stock worth $53,470,000 after purchasing an additional 23,299 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of SI-BONE by 1.8% in the first quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock worth $40,328,000 after purchasing an additional 43,670 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of SI-BONE by 104.8% in the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock worth $40,158,000 after purchasing an additional 1,255,610 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its position in shares of SI-BONE by 13.2% in the fourth quarter. Granahan Investment Management LLC now owns 1,286,450 shares of the company’s stock worth $27,003,000 after purchasing an additional 150,217 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.